Amgen Antigen Binding Proteins Targeting Beta-Klotho and FGF Receptors
Summary
The European Patent Office granted Amgen Inc. Patent EP3760642A1 covering human antigen binding proteins that bind beta-Klotho, FGF receptors, and complexes thereof. The patent covers therapeutic applications including treatment of metabolic conditions (A61P 3/04). The patent is designated for all 31 European states including DE, FR, GB, IT, ES, NL, SE, and 21 others.
What changed
EPO published EP3760642A1, a granted patent for Amgen Inc. covering human antigen binding proteins (antibodies) specific to beta-Klotho and FGF receptors and their complexes. The patent spans multiple IPC classifications including C07K 16/18, C07K 16/28, A61K 39/395, and therapeutic indication A61P 3/04 (anti-obesity/metabolic). Inventors include Hu, Foltz, King, Li, and Arora.
Pharmaceutical manufacturers and biotech companies developing FGF19/FGF21 pathway therapeutics or beta-Klotho-targeted biologics in Europe will need to assess Freedom to Operate considerations before commercializing related products. The patent provides Amgen with enforceable exclusive rights in designated EU states for the stated protein compositions and their therapeutic uses.
Archived snapshot
Apr 18, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
HUMAN ANTIGEN BINDING PROTEINS THAT BIND BETA-KLOTHO, FGF RECEPTORS AND COMPLEXES THEREOF
Publication EP3760642A1 Kind: A1 Apr 08, 2026
Applicants
Amgen Inc.
Inventors
Hu, Shaw-Fen Sylvia, Foltz, Ian, King, Chadwick T., Li, Yang, Arora, Taruna
IPC Classifications
C07K 16/18 20060101AFI20201118BHEP C07K 16/28 20060101ALI20201118BHEP A61K 39/395 20060101ALI20201118BHEP A61P 3/04 20060101ALI20201118BHEP C07K 19/00 20060101ALI20201118BHEP C07K 14/71 20060101ALI20201118BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Named provisions
Related changes
Get daily alerts for EPO Patent Bulletin - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when EPO Patent Bulletin - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.